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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.014Bacterial-derived lipopolysaccharides (LPS) play an essential role in the inﬂammatory process of inﬂam-
matory bowel disease. A defective intestinal tight junction (TJ) barrier is an important pathogenic factor of
inﬂammatory bowel disease and other inﬂammatory conditions of the gut. Despite its importance in medi-
ating intestinal inﬂammation, the physiological effects of LPS on the intestinal epithelial barrier remain
unclear. Themajor aims of this study were to determine the effects of physiologically relevant concentrations
of LPS (0 to 1 ng/mL) on intestinal barrier function using an in vitro (ﬁlter-grown Caco-2 monolayers) and an
in vivo (mouse intestinal perfusion) intestinal epithelial model system. LPS, at physiologically relevant
concentrations (0 to 1 ng/mL), in the basolateral compartment produced a time-dependent increase in Caco-
2 TJ permeability without inducing cell death. Intraperitoneal injection of LPS (0.1 mg/kg), leading to
clinically relevant plasma concentrations, also caused a time-dependent increase in intestinal permeability
in vivo. The LPS-induced increase in intestinal TJ permeability was mediated by an increase in enterocyte
membrane TLR-4 expression and a TLR-4edependent increase in membrane colocalization of membrane-
associated protein CD14. In conclusion, these studies show for the ﬁrst time that LPS causes an increase
in intestinal permeability via an intracellular mechanism involving TLR-4edependent up-regulation of CD14
membrane expression. (Am J Pathol 2013, 182: 375e387; http://dx.doi.org/10.1016/j.ajpath.2012.10.014)Supported by a Veterans Affairs (VA) Merit Review grant from the VA
Research Service and by National Institute of Diabetes and Digestive and
Kidney Diseases grants RO 1-DK-64165e01 and RO 1-DK-081429
(T.Y.M.). The UNM & Cancer Center Fluorescence Microscopy Shared
Resource is supported by NCI P30 CA118100 (C. Willman), NCRR
1S10RR025540 (A. Wandinger-Ness), NIDDK 3R301 DK050141 (A.
Wandinger-Ness), and NIGMS P50 GM085273 (J. Oliver).An integral function of intestinal epithelial cells is to act as
a physical barrier, separating the noxious luminal environ-
ment from the underlying lamina propria and the deeper
intestinal layers.1,2 The apically located tight junctions (TJs)
form a paracellular seal between the lateral membranes of
adjacent intestinal epithelial cells, and act as a structural
and functional barrier against paracellular ﬂux of luminal
substances. Defective intestinal epithelial TJ barrier has been
shown to be an important pathogenic factor of inﬂammatory
bowel disease (IBD) and necrotizing enterocolitis (NEC) by
allowing paracellular permeation of luminal antigens that
elicit and promote inﬂammatory response.1,2 Both clinical
and animal studies have shown the importance of a defective
intestinal TJ barrier in the development and prolongation of
intestinal inﬂammation in IBD and NEC.1e5 These studies
have shown that normalization of intestinal barrier in patients
with active Crohn’s disease predicts prolonged clinicalstigative Pathology.
.remission, whereas a persistent increase in intestinal perme-
ability portends poor clinical outcome with rapid recurrence
of the disease.6,7 Additionally, animal studies have also
shown that a primary defect in intestinal junctional complexes
was sufﬁcient to induce or aggravate intestinal inﬂammation
inmurinemodels of IBD,8,9 whereas therapeutic tightening or
enhancement of the intestinal TJ barrier prevented the
development of intestinal inﬂammation.3,10
The terms endotoxin and lipopolysaccharide (LPS) are
used interchangeably and refer to the major cell wall
Guo et alcomponent of Gram-negative bacteria.11,12 LPS are complex
amphiphilic molecules having a hydrophobic (consisting of
lipid A) and a hydrophilic (consisting of carbohydrate core
and polysaccharide O-antigen) component and are released
from bacterial cell wall by shedding or through bacterial
lysis.11e13 LPS concentrations are highest in the gut lumen,
where many trillions of commensal bacteria reside. Nor-
mally, LPS in the gut lumen do not penetrate across the
healthy intestinal epithelium14,15; however, in intestinal
permeability disorders, the defective TJ barrier allows par-
acellular ﬂux of LPS and other luminal antigens.11e13,16e19
The intestinal tissue and circulating LPS levels are markedly
elevated in IBD and NEC, and play an important role in
mediating inﬂammatory response.11e13,16e18 The involve-
ment of LPS in the initiation and propagation of intestinal
inﬂammation in IBD and NEC has been well demon-
strated.20e23 These studies have shown LPS to be an
important contributing factor of intestinal inﬂammation, and
removal of circulating LPS accelerated the clinical
improvement of IBD and NEC.20,22,23 Despite the impor-
tance of a defective intestinal barrier in the accentuation and
prolongation of intestinal inﬂammation in IBD and
NEC,3,6,9,20,22 the effects of circulating levels of LPS on the
intestinal epithelial barrier remain unknown. Because LPS
levels are markedly elevated in these diseases and play an
important role in the inﬂammatory process, understanding
the effects of LPS on intestinal barrier function has impor-
tant potential clinical signiﬁcance.
In normal healthy individuals, plasma concentrations
of LPS range from undetectable levels up to 0.2
ng/mL.11,12,20,22 A variety of physiological factors such as
prolonged physical exertion, high-fat diet, physiological
stresses, or heat can lead to elevated plasma LPS levels as
high as 1 to 2 ng/mL.24e27 Patients with intestinal perme-
ability disorders such as Crohn’s disease, NEC, acute
pancreatitis, alcoholic liver disease, and critical illnesses
also have elevated plasma LPS levels ranging up to 2 to 10
ng/mL.11e13,20,22,28 Based on these reports, we consider
LPS levels of 0 to 1.0 ng/mL to be physiologically relevant
and 0 to 10 ng/mL to be clinically relevant. (For reference,
the concentration of LPS in the gut lumen has been reported
to be 1.8 mg/mL in the rat distal ileum.29,30) Inexplicably, in
most of the published studies, extreme pharmacological
concentrations of LPS ranging between 50 and 1000 mg/mL,
which exceed the physiologically achievable concentrations
by 104- to 107-fold, have been used to assess various bio-
logical responses.30e34 At these extreme concentrations,
LPS causes rapid cell death in various cell types studied,
including in intestinal and immune cells,30,33e35 and does
not provide accurate depiction of biological activity of LPS.
Herein, we show that LPS, at physiologically and clinically
relevant concentrations (0 to 10 ng/mL), does not cause
intestinal epithelial cell death, but causes a selective increase
in intestinal TJ permeability in vitro and in vivo. These
studies also show for the ﬁrst time that pattern recognition
receptors Toll-like receptor 4 (TLR-4) and CD14 play376a central role in the modulation of the intestinal epithelial TJ
barrier.
Materials and Methods
Reagents
Dulbecco’s modiﬁed Eagle’s medium, trypsin, fetal bovine
serum, glutamine, penicillin, streptomycin, PBS, and
horseradish peroxidaseeconjugated secondary antibodies
for Western blot analysis were purchased from Invitrogen/
Life Technologies (Carlsbad, CA). Small-interfering RNA
(siRNA) of TLR-4, CD14, and transfection reagents were
from Dharmacon/Thermo Fisher Scientiﬁc (Lafayette, CO).
LPS (O111:B4) was purchased from Sigma-Aldrich
(St. Louis, MO). All other chemicals were of reagent
grade and were purchased from Sigma-Aldrich, VWR
(Aurora, CO), or Fisher Scientiﬁc (Pittsburgh, PA).
Cell Culture
Caco-2 cells (passage 20) were purchased from ATCC
(Manassas, VA) and maintained at 37C in a culture medium
composed of Dulbecco’s modiﬁed Eagle’s medium with
4.5 mg/mL glucose, 50 U/mL penicillin, 50 U/mL strepto-
mycin, 4 mmol/L glutamine, 25 mmol/L HEPES, and 10%
fetal bovine serum as previously described.36,37 Caco-2 cells
were used between passages 22 and 28 in this study. The
human-derived, nontransformed colonic epithelial cell line
NCM460 was maintained in M3:10 medium (INCELL, San
Antonio, TX), but was shifted to Ham’s F-12 culture medium
supplemented with 20% fetal bovine serum and antibiotics as
previously described.38 NCM460 cells were used between
passages 29 and 39 in this study. T84 intestinal epithelial
cells (passage 53) were purchased from ATCC (Rockville,
MD) and maintained at 37C in Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F-12 medium supplemented with 16 mmol/L
NaHCO3, antibiotics, and 5% fetal bovine serum, as previ-
ously described.39 Only T84 cells from passages 55 to 61
were used to maintain consistency. The cells were kept at
37C in a 5% CO2 environment. For growth on ﬁlters, high-
density cells (1  105 cells) were plated on Transwell ﬁlters
with 0.4-mm pore size (Corning Incorporated, Corning, NY)
and monitored regularly by visualization with an inverted
microscope (Eclipse TS100/100-F; Nikon, Melville, NY)
and by epithelial resistance measurements.
Determination of Epithelial Monolayer Resistance and
Paracellular Permeability
Caco-2 transepithelial electrical resistance (TER) was
measured by using an epithelial voltohmeter (World Precision
Instruments, Sarasota, FL) as previously reported.36,37 Both
apical and basolateral sides of the epitheliumwere bathed with
buffer solution. Electrical resistancewasmeasured until similar
values were recorded on three consecutive measurements.ajp.amjpathol.org - The American Journal of Pathology
LPS Modulation of Intestinal TJ BarrierCaco-2 paracellular permeability was determined by using an
established paracellular marker inulin. Known concentrations
of permeability marker (10 mmol/L) and its radioactive tracer
were added to the apical solution.36 Low concentrations of
permeability markers were used to ensure that negligible
osmotic or concentration gradients were introduced.
Assessment of Protein Expression by Western Blot
Analysis
Protein expression from Caco-2 cells and mouse tissue was
assessed by Western blot as previously described.36,37 Cells
and mouse tissue were lysed with lysis buffer [50 mmol/L
Tris-HCl (pH 7.5), 150 mmol/L NaCl, 500 mmol/L NaF,
2 mmol/L EDTA, 100 mmol/L vanadate, 100 mmol/L phe-
nylmethylsulfonyl ﬂuoride, 1 mg/mL leupeptin, 1 mg/mL
pepstatin A, 40 mmol/L para-nitrophenyl phosphate, 1 mg/mL
aprotinin, and 1% Triton X-100]. The lysates were centri-
fuged at 10,000  g for 10 minutes in an Eppendorf
Centrifuge (5417R; Hauppauge, NY) to obtain a clear lysate.
The supernatant was collected and protein concentration was
determined using the Bio-Rad Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA). Laemmli gel loading buffer
(Bio-Rad Laboratories) was added to the lysate containing 10
to 20 mg of protein and boiled at 100C for 7 minutes, after
which proteins were separated on an SDS-PAGE gel.
Proteins from the gel were transferred to the membrane
(Trans-Blot Transfer Medium, nitrocellulose membrane;
Bio-Rad Laboratories) overnight. The membrane was incu-
bated for 2 hours in blocking solution (5% dry milk in TBS-
Tween 20 buffer). The membrane was then incubated with
antibody in blocking solution. After a wash in TBS-1%
Tween buffer, the membrane was incubated in secondary
antibody and developed using Santa Cruz Western Blotting
Luminol Reagents (Santa Cruz Biotechnology, Santa Cruz,
CA) on Kodak BioMaxMS ﬁlm (Fisher Scientiﬁc). The ﬁlms
were exposed between 5 seconds and 10 minutes.
Assessment of Apoptosis
Caco-2 apoptosis was assessed using the CytoGLO Annexin
V-FITC Apoptosis Detection kit from Imgenex as previously
described.37 Following appropriate treatments, apoptosis was
measured by ﬂow cytometry using a FACScan ﬂow cytom-
eter (BD Biosciences, San Jose, CA). For each experimental
sample, a total of 10,000 cells were counted for Annexin
V-FITC and propidium iodide stain.
Proliferation Assay
Cell proliferation was measured using Quick Cell Prolifera-
tion Assay kit (ab65473; Abcam, Cambridge, MA) according
to the manufacturer’s instructions. This assay is based on
cleavage of the tetrazolium salt WST-1 to formazan by
cellular mitochondrial dehydrogenases. Cell proliferation
is accompanied by an increase in the activity of theThe American Journal of Pathology - ajp.amjpathol.orgmitochondrial dehydrogenases, which leads to an increase in
conversion of tetrazolium salt, WST-1, to formazan. Brieﬂy,
Caco-2 cells (1  105 cells) were plated on Transwell ﬁlters.
After LPS treatment, tetrazolium salt WST-1 solution was
added to each ﬁlter, and the reaction was allowed to occur in
standard culture condition for 4 hours. The optical density
(formazan formation) was measured at 440 nm with a refer-
ence wavelength of 650 nm using a precision microplate
reader (Molecular Devices, Sunnyvale, CA) as a measure of
mitochondrial dehydrogenase activity.
Immunostaining
Colocalization of TLR-4 and CD14 was assessed by immu-
noﬂuorescent antibody labeling.40 Caco-2 monolayers or
frozen mouse intestinal sections were washed and ﬁxed with
2% paraformaldehyde. After being permeabilized with 0.1%
Triton X-100 in PBS, Caco-2 monolayers or intestinal tissues
were incubated in blocking solution composed of bovine
serum albumin and normal donkey serum in PBS for 1 hour,
then labeled with primary antibodies in blocking solution
overnight at 4C, followed by ﬂuorescein isothiocyanate or
Cy3-conjugated secondary antibodies for 1 hour at room
temperature. ProLong Gold Antifade reagent (Invitrogen) was
used to mount the ﬁlters onto coverslips. Immunolocalizations
of TLR-4 and CD14 were visualized using a confocal ﬂuo-
rescence microscope (LSM 510Meta Confocal; University of
New Mexico Fluorescence Microscopy Shared Resource)
equipped with a Hamamatsu Digital Camera 9 (Hamamatsu
Photonics, Hamamatsu, Japan). Images were processed with
LSM software (Carl Zeiss, Oberkochen, Germany).
siRNA Transfection
Caco-2 monolayers were transiently transfected with siRNA
using DharmaFect transfection reagent (Dharmacon/Thermo
Fisher Scientiﬁc) as previously described.40 Brieﬂy, cells
(1  105/ﬁlter) were seeded into a 12-well Transwell plate
and grown to conﬂuency. Caco-2 monolayers were then
washed with PBS twice; 0.5 mL Accell medium (Thermo
Fisher Scientiﬁc) was added to the apical compartment of
each ﬁlter, and 1.5 mL were added to the basolateral
compartment of each ﬁlter. siRNA (5 ng) of interest and
DharmaFect reagent (2 mL) were preincubated in Accell
medium. After 5 minutes of incubation, the two solutions
were mixed, and the mixture was added to the apical
compartment of each ﬁlter. For LPS experiments, Caco-2
cells were transfected with siRNA for 24 hours before the
LPS treatment. The Caco-2 TJ barrier assessments were
performed at the end of day 5 of LPS treatment.
In Vivo Determination of Mouse Intestinal Permeability
and LPS Plasma Level
The Laboratory Animal Care and Use Committee at the
University of New Mexico approved all experimental377
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Figure 1 Effect of LPS on Caco-2 TJ permeability. A: Effect of increasing
concentrations of LPS (0, 0.1, 0.3, 0.5, 1, 5, and 20 ng/mL) on Caco-2 TER.
The mean TER for control (Cont) Caco-2 monolayers was 481  5 U  cm2.
B: Effect of increasing concentrations of LPS (0, 0.1, 0.3, 0.5, 1, 5, and
20 ng/mL) on Caco-2 transepithelial ﬂux of paracellular marker inulin. Filter-
grown Caco-2 monolayers were treated with LPS for a 5-day experimental
period. C: Time-course effect of LPS (0.3 ng/mL) on Caco-2 TER. The mean
TER for day 0 was 450 14U  cm2. D: Time-course effect of LPS (0.3 ng/mL)
on Caco-2 inulin ﬂux. The effect of LPS (0.3 ng/mL) on Caco-2 TER and inulin
ﬂux were measured over a 7-day experimental period. E: Graph of TER versus
inulin ﬂux (r Z 0.93). F: Time course of Caco-2 TER recovery after LPS
(0.3 ng/mL) removal. LPS was removed from the basolateral compartment
after 5 days of treatment (arrow). The mean TER for control Caco-2 mono-
layers was 486  28 U  cm2. *P < 0.0001 versus control.
Guo et alprotocols. Male C57BL/6 mice, TLR-4 knockout mice, and
CD14 knockout mice (9 to 10 weeks) were purchased from
the Jackson Laboratories (Bar Harbor, ME). The mice were
kept two per cage in a temperature-controlled room at 25C
with a 12:12-hour lightedark cycle. Diet and drinking water
were provided ad libitum.
LPS effect on intestinal permeability in an in vivo mouse
model system was determined using a recycling intestinal
perfusion method as previously described.36,40,41 Mice were
injected with varying concentrations of LPS intraperitoneally
(i.p.) every 24 hours for up to 5 days of the experimental
period. A 6-cm segment of mouse small intestine was
isolated and cannulated with a small-diameter plastic tube (in
an anesthetized mouse maintained on 1% isoﬂurane in
oxygen) and continuously perfused with 5 mL of Krebs-
phosphate saline buffer for a 2-hour perfusion period.36,40
An external recirculating pump (Econo Pump; Bio-Rad
Laboratories) was used to recirculate the perfusate at
a constant ﬂow rate (0.75 mL/min). The body temperature of
the mouse was maintained at 37C with a temperature-
controlled warming blanket. The intestinal permeability
was assessed by measuring the ﬂux rate of the paracellular
probe, Texas Redelabeled dextran (MW Z 10,000 g/mol).
Water absorption was determined by using a nonabsorbable
marker, sodium ferrocyanide, or by measuring the difference
between the initial and ﬁnal volumes of the perfusate. The
plasma LPS level was measured using Limulus Amebocyte
Lysate Assay (Associates of Cape Cod, E. Falmouth, MA).
Statistical Analysis
Results are expressed as means  SE, and analyzed using
Student’s t-test for unpaired data (GraphPad Prism version
5.00 for Windows; GraphPad Software, La Jolla, CA). A
P value of 0.05 was used to indicate statistical signiﬁ-
cance. All experiments were repeated at least three times to
ensure reproducibility.
Results
LPS Effect on Caco-2 Intestinal Epithelial TJ
Permeability
The effects of physiologically and clinically achievable
concentrations of LPS (0 to 10 ng/mL) on intestinal
epithelial TJ permeability was determined in vitro by
measuring TER and mucosal-to-serosal ﬂux of paracellular
marker inulin in ﬁlter-grown Caco-2 intestinal monolayers,
over a 5-day experimental period. LPS (0, 0.1, 0.3, 0.5, 1, 5,
and 20 ng/mL) caused a concentration-dependent drop in
Caco-2 TER (Figure 1A) and an increase in inulin ﬂux
(Figure 1B). LPS caused a signiﬁcant drop in TER and an
increase in inulin ﬂux at a concentration of 0.3 ng/mL.
Increasing the LPS concentration above 0.3 ng/mL caused
only a minimal additional drop in Caco-2 TER (Figure 1A)
or increase in inulin ﬂux (Figure 1B). These results378indicated that LPS at concentrations of 0.3 ng/mL or above
cause an increase in Caco-2 TJ permeability. (In subsequent
experiments, a LPS concentration of 0.3 ng/mL was used,
unless stated otherwise.)
Next, the time-course effect of LPS (0.3 ng/mL) on
Caco-2 TJ permeability was determined. LPS did not have
signiﬁcant effect on Caco-2 TER up to day 3, but caused
a drop in TER between days 4 and 5. The drop in TER
reached a trough level by day 5 and remained unchanged up
to day 7 (Figure 1C). Conversely, LPS caused an increase in
mucosal-to-serosal inulin ﬂux by day 4, and the increase in
inulin ﬂux persisted up to day 7 (Figure 1D). A similar time-
course effect was also observed for higher concentrations of
LPS (1 and 20 ng/mL) (data not shown). The plot of the
LPS-induced drop in TER and increase in paracellular ﬂuxajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Time-course effect of LPS (0.3 ng/mL) on NCM460 TER (A) and
T84 TER (B). The mean TER for NCM460 monolayers at day 0 was 418 
14 U  cm2, and the mean TER for T84 monolayers at day 0 was 1570 
108 U  cm2. *P < 0.0001 versus control.
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Figure 3 Membrane speciﬁcity of the LPS effect on Caco-2 perme-
ability. A: Effect of LPS (0.3 ng/mL) on Caco-2 TER. The mean TER for
control (Cont) Caco-2 monolayers was 475  12 U  cm2. B: Effect of LPS
(0.3 ng/mL) on Caco-2 inulin ﬂux. LPS (0.3 ng/mL) was added to either
apical (AP), basolateral (BL), or combined apical and basolateral
compartments (Both) for the 5-day experimental period. C: Effect of
increasing concentrations of LPS (0, 0.1, 0.3, 1, 20, 1000, and 50,000
ng/mL) on Caco-2 TER. The mean TER for control Caco-2 monolayers was
454  19 U  cm2. D: Effect of increasing concentrations of LPS (0, 0.1,
0.3, 1, 20, 1000, and 50,000 ng/mL) on Caco-2 inulin ﬂux. LPS was added
to the apical compartment at each 24 hours treatment period for 5 days.
*P < 0.0001 versus control.
LPS Modulation of Intestinal TJ Barrierdemonstrates a linear relationship (relative correlation
coefﬁcient, rZ 0.93) between the drop in Caco-2 TER and
the increase in inulin ﬂux (Figure 1E), indicating that the
LPS-induced drop in Caco-2 TER correlates with an
increase in paracellular permeability. The time course of
Caco-2 TER recovery following LPS removal was also
examined. The removal of LPS after 5 days of treatment
resulted in full restoration of the Caco-2 TER within 2 days
of removal (Figure 1F).
To conﬁrm that the LPS effect extends to other intestinal
epithelial cell lines, we also examined the effect of LPS (0.3
ng/mL) on NCM460 and T84 monolayer TER. NCM460 is
a human-derived, nontransformed colonic epithelial cell
line, and T84 is a colon cancerederived cell line having
high TER. LPS caused a similar time-dependent drop in
NCM460 and T84 TER (Figure 2) as in the Caco-2
monolayers. There was an approximately 30% drop in
TER by day 4 or 5 of LPS treatment. Because LPS prepa-
ration is known to contain traces of impurities, including
cytokines and other lipoproteins, the effect of heat-
inactivated LPS (exposure to 121C for 30 minutes) on
Caco-2, NCM460, and T84 TER was also examined. Heat-
inactivated LPS did not affect the TER of intestinal mono-
layers (data not shown), suggesting that the impurities in
LPS did not affect the intestinal monolayer TER and that
active LPS was required for the drop in TER.
To assess the membrane speciﬁcity of LPS effect, LPS (0.3
ng/mL) was added to either the apical, basolateral, or
combined apical and basolateral compartments. The addition
of LPS to the apical solution did not have a signiﬁcant effectThe American Journal of Pathology - ajp.amjpathol.orgon Caco-2 TER (Figure 3A) or inulin ﬂux (Figure 3B),
whereas the addition of LPS to the basolateral solution
caused a drop in Caco-2 TER and an increase in inulin
ﬂux. The addition of LPS to both apical and basolateral
compartments caused a similar change in TJ permeability as
the basolateral compartment alone (Figure 3, A and B). To
investigate the possibility that the LPS effect on the apical
membrane may be concentration related, higher concentra-
tions of LPS were also added to the apical solution. The
higher concentrations (20 ng/mL, 1 mg/mL, and 50 mg/mL) of
LPS in the apical membrane surface also did not affect Caco-
2 TER or inulin ﬂux (Figure 3, C and D), suggesting that the
presence of high concentrations of LPS on the mucosal
surface do not affect intestinal TJ barrier function.
LPS Effect on Caco-2 Apoptosis and Cell Death
In previous studies, the effects of high pharmacological
concentrations (50 mg/mL to 1 mg/mL) of LPS on intestinal
epithelial barrier integrity were evaluated.30e32 These studies
indicated that at these extreme concentrations (which exceed
the physiological levels by 104- to 107-fold), LPS causes
a rapid apoptosis and death of intestinal epithelial cells
and apoptosis-dependent loss of epithelial integrity.30e32
However, the effects of physiologically relevant concentra-
tions of LPS (0 to 1 ng/mL) on intestinal epithelial cell379
Guo et alapoptosis or death remain unclear. The LPS effect on Caco-2
apoptosis and necrosis was determined over a 5-day experi-
mental period by Annexin V-FITC labeling of phosphati-
dylserine on plasma membrane of apoptotic cells and by
propidium iodide labeling of DNA in necrotic cells using
ﬂow cytometry37 and by caspase-3 expression in ﬁlter-grown
Caco-2 monolayers.30 Increasing the concentration of LPS
up to 100 ng/mL did not induce Caco-2 cell apoptosis
(Figure 4A) or necrosis (data not shown). As a positive
control, Caco-2 monolayers were also treated with high LPS
concentration (1 mg/mL) that had been previously shown to
induce Caco-2 cell apoptosis (Figure 4A). In separate
experiments, the time-course effect of LPS (0.3 ng/mL) on
caspase-3 expression in Caco-2 monolayers was also exam-
ined. LPS did not cause an increase in caspase-3 expression
(Figure 4B). Additionally, the LPS effect on morphology of
Caco-2 monolayers was examined using a Nikon inverted
microscope (400 magniﬁcation). LPS (0 to 100 ng/mL)
did not cause morphological changes to the epithelial
monolayer surface or detachment of epithelial cells (data not
shown). To examine the effect on cell turnover, we also
measured the effect of LPS (0.3 ng/mL) on cell proliferation
over a 5-day experimental period by assessing mitochondrial
dehydrogenase activity. LPS did not have a signiﬁcant effect
on Caco-2 cell proliferation (Figure 4C). Together, these
results indicate that LPS at concentrations up to 100 ng/mL
does not induce Caco-2 cell death and that the LPS effect on
Caco-2 TJ permeability is not due to cell death leading to
a breach in the epithelial integrity.
LPS-Induced Increase in Caco-2 TJ Permeability
Requires an Increase in TLR-4 Expression
In the following studies, the possible involvement of TLR-2,
TLR-4, or TLR-5 in the LPS-induced increase in Caco-20 0.1 0.3 1 100 106
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Figure 4 Effect of LPS on Caco-2 cell apoptosis and proliferation. A: Effect of
ﬂow cytometry. LPS concentration of 1 mg/mL was used as a positive control of ap
LPS on caspase-3 expression assessed by Western blot analysis. C: Effect of LPS
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380TJ permeability was determined. The basal expressions
of TLR-2 and TLR-4 were low in unstimulated Caco-2
monolayers, whereas TLR-5 levels were higher (Figure 5A).
LPS (0.3 ng/mL) treatment resulted in a time-dependent
increase in TLR-4 expression (Figure 5A), but did not
signiﬁcantly affect TLR-2 or TLR-5 levels. LPS did not
cause an increase in TLR-4 expression until day 4 of the
treatment. The time course of the LPS-induced increase
in Caco-2 TLR-4 expression paralleled the drop in
Caco-2 TER and the increase in paracellular permeability
(Figure 1, C and D), suggesting a possible cause-and-
effect relationship. To determine the possible causal role
of TLR-4 in the LPS-induced increase in Caco-2 TJ
permeability, the effect of siRNA-induced silencing of
TLR-4 expression was examined. The TLR-4 siRNA
transfection resulted in an inhibition of the LPS-induced
increase in Caco-2 TLR-4 expression (Figure 5B), drop
in Caco-2 TER (Figure 5C), and increase in inulin ﬂux
(Figure 5D), conﬁrming the speciﬁc requirement of TLR-
4 in LPS-induced increase in Caco-2 TJ permeability. In
a separate set of experiments, the requirement of TLR-2 or
TLR-5 in the LPS-induced increase in Caco-2 TJ
permeability was also examined. The siRNA-induced
knockdown of TLR-2 or TLR-5 did not affect the LPS-
induced drop in Caco-2 TER or the increase in inulin
ﬂux (Figure 6). To further validate the involvement of
TLR-4 signal transduction pathway, the effect of a phar-
macological inhibitor of the TLR-4 pathway, TAK-242,42
on the LPS-induced increase in Caco-2 TJ permeability
was examined. TAK-242 (3 mmol/L) prevented the LPS-
induced drop in Caco-2 TER (Figure 5E) and the
increase in inulin ﬂux (Figure 5F). Together, these ﬁnd-
ings suggest that the LPS effect on Caco-2 TJ perme-
ability is mediated by an increase in TLR-4 expression
and activation of the TLR-4 signal transduction pathway.  2      3      4       5
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LPS Modulation of Intestinal TJ BarrierLPS Causes an Increase in Mouse Intestinal
Permeability in Vivo
In the following studies, an in vivo model of the LPS-
induced increase in mouse intestinal permeability was
established, using a modiﬁcation of a previously described
method of recycling mouse intestinal perfusion.36,40,41 To
determine the appropriate LPS concentration to use in vivo,
the effects of increasing i.p. doses of LPS (0, 0.05, 0.1, 1.0,
or 10 mg/kg body weight) on mouse plasma LPS level were
determined. The basal plasma LPS level in control mice
(C57BL/6, the Jackson Laboratory, Bar Harbor, ME) was
0.017 ng/mL; increasing the i.p. LPS concentration resulted
in a dose-dependent increase in mouse plasma LPS levels
(Table 1). The LPS concentration of 0.1 mg/kg body weight
produced a 1-hour peak level of 2.230 ng/mL and a 24-hour
steady-state plasma level of 0.405 ng/mL (Table 1), which
were within physiologically and clinically relevant plasmaFigure 5 Effect of LPS on Toll-like receptors. A: Time-course effect of
LPS on TLR-2, TLR-4, and TLR-5 expression in Caco-2 monolayers. B: Effect
of TLR-4 siRNA transfection on TLR-4 expression in Caco-2 monolayers.
Effect of inhibition of TLR-4 by siRNA silencing on Caco-2 TER (C) and inulin
ﬂux (D). The Caco-2 cells were transfected with TLR-4 siRNA, 24 hours
before the LPS treatment. The mean TER for control (Cont) Caco-2 mono-
layers was 441  4 U  cm2. Effect of TLR-4 inhibitor, TAK-242 (3 mmol/L),
on Caco-2 TER (E) and inulin ﬂux (F). TAK-242 was added to the apical
compartment 1 hour before the LPS treatment. The mean TER for control
Caco-2 monolayers was 463  15 U  cm2. Scr, scrambled. *P < 0.001
versus control; **P < 0.001 versus LPS treatment.
Figure 6 Effect of siRNA silencing of TLR-2 or TLR-5 on LPS-induced
alteration in Caco-2 TER and inulin ﬂux. Caco-2 cells were transfected
with TLR-2 siRNA or TLR-5 siRNA for 24 hours before the LPS treatment.
siRNA-induced silencing of TLR-2 did not affect Caco-2 TER (A) or inulin ﬂux
(B). The mean TER for control Caco-2 monolayers was 468  17 U  cm2.
siRNA-induced silencing of TLR-5 also did not affect Caco-2 TER (C) or
inulin ﬂux (D). The mean TER for control Caco-2 monolayers was 492 
24 U  cm2. Scr, scrambled. *P < 0.001 versus control.
The American Journal of Pathology - ajp.amjpathol.orgconcentrations.11e13,20,22 By contrast, the lethal LPS dose
(10 mg/kg) used in previous animal studies32 resulted in
very high peak (13.49 mg/mL) and trough (252.4 ng/mL)
plasma LPS levels, which produced a rapid intestinal
mucosal damage (Table 1). On the basis of the above data,
the LPS dose of 0.1 mg/kg was selected for the mouse
intestinal permeability studies. Over a 5-day treatment
period (LPS injection every 24 hours), the steady-state
plasma LPS level remained between 0.4 and 0.5 ng/mL
(Figure 7A). Similar to the in vitro studies, intraperitoneal
LPS (0.1 mg/kg) injection did not have a signiﬁcant effect
on mouse intestinal permeability up to day 3, as assessed by
mucosal-to-serosal ﬂux of Texas Rededextran 10 kDa, but
caused an increase in intestinal permeability at day 5
(Figure 7B). LPS (0.1 mg/kg) treatment did not cause
intestinal mucosal damage (Figure 7C) or changes in mouse
behavior or body weight (data not shown). These dataTable 1 Effect of Increasing Concentration of i.p. LPS (0, 0.05,
0.1, 1.0, 10.0 mg/kg Body Weight) on Mouse Plasma LPS Level
in Vivo
LPS
(mg/kg)
0 hours
(ng/mL)
1 hour
(ng/mL)
24 hours
(ng/mL)
0.05 0.017 0.366 0.020
0.1 0.017 2.230 0.405
1 0.018 1327.1 20.732
10 0.018 13,491.0 252.427
Plasma LPS level was measured prior to i.p. LPS injection and 1 hour and
24 hours post-LPS injection (n Z 3 to 4).
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Guo et alindicate that LPS, at clinically relevant plasma concentra-
tions, causes an increase in mouse intestinal permeability
without causing acute intestinal mucosal damage.
Next, the involvement of TLR-4 in the LPS-induced
increase in mouse intestinal permeability was examined.
Intraperitoneal LPS (0.1 mg/kg) caused a time-dependent
increase in intestinal tissue TLR-4 expression (Figure 7D).
In the control mice, there was only minimal expression of
TLR-4 in the intestinal tissue. LPS treatment did not affect
TLR-4 expression up to day 3; however, by day 5, there was
a marked increase in TLR-4 expression (Figure 7D). The
time course of TLR-4 expression paralleled the increase in
mouse intestinal permeability (Figure 7B). To determine the
requirement of TLR-4 in the LPS-induced increase in mouse
intestinal permeability, the LPS effect was examined in0 1 3 5
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Figure 7 Effect of i.p. LPS (0.1 mg/kg body weight) on mouse intes-
tinal permeability and plasma TLR-4 level. A: Time-course effect of i.p. LPS
on plasma LPS level in mice. B: Time-course effect of i.p. LPS on intestinal
permeability. C: Effect of LPS administration on intestinal tissue: wild-type
(WT); LPS 1 day treatment; LPS 5 days treatment. H&E stain, original
magniﬁcation, 200. D: Time-course effect of LPS on TLR-4 expression in
mice. E: Effect of LPS on intestinal permeability in TLR-4/ mice. *P <
0.001 versus WT control; **P < 0.001 versus WT LPS treatment.
382TLR-4 deﬁcient mice (C57BL/6 Tlr4lps-d, the Jackson
Laboratory). Intraperitoneal LPS did not cause an increase
in intestinal permeability in TLR-4/ mice (Figure 7E),
indicating that TLR-4 was also required for the LPS-
induced increase in mouse intestinal permeability.
LPS-Induced Increase in Mouse Intestinal TJ
Permeability Is Mediated by a TLR-4eDependent
Up-Regulation and Membrane Recruitment of CD14
TLR-4 forms an aggregate receptor complex with
membrane-associated proteins CD14 and myeloid differen-
tiation protein 2 (MD2) and other adaptor proteins.43,44
CD14 appears to be the receptor protein involved in the
binding of LPS/LPS binding protein complex.43,44 In the
following studies, the LPS effect on expression and locali-
zation of TLR-4 and CD14 in Caco-2 monolayers was
examined by immunostaining and imaging by confocal
microscopy. In the control Caco-2 monolayers, there was
only minimal TLR-4 and CD14 expression (Figure 8). LPS
(0.3 ng/mL) treatment caused a time-dependent increase in
TLR-4 expression, both in the cytoplasm and at the level of
the plasma membrane; and by day 5, a marked increase in
plasma membrane localization of TLR-4 was seen
(Figure 8). Corresponding to the increase in TLR-4
expression and membrane localization, there was also an
increase in cellular expression and membrane colocalization
of CD14 by day 5 (Figure 8). The time course of the LPS-
induced increase in CD14 expression was also conﬁrmed by
immunoblot analysis (Figure 9A). Next, the involvement of
CD14 in the LPS-induced increase in Caco-2 TJ perme-
ability was examined. The siRNA-induced knockdown of
CD14 prevented the LPS-induced drop in Caco-2 TER
(Figure 9B) and increase in paracellular permeability
(Figure 9C), indicating that CD14 expression was also
required for the LPS-induced increase in Caco-2 TJ
permeability. In the following studies, the possible depen-
dence of CD14 expression and membrane localization on
TLR-4 expression was examined. The siRNA-induced
knockdown of TLR-4 inhibited the LPS-induced increase
in Caco-2 CD14 expression (Figure 9D) and membrane
localization (Figure 8), suggesting that the increase in TLR-
4 was required for the increase in CD14 expression.
Next, the role of TLR-4/CD14 receptor complex in the
LPS-induced increase in intestinal permeability was also
determined in vivo. In the control mice, there was only
a minimal expression of TLR-4 or CD14 in mouse enter-
ocytes (Figure 10A). LPS administration (0.1 mg/kg i.p.)
resulted in a marked increase in mouse enterocyte TLR-4
and CD14 expression, both in the cytoplasm and at the
level of the plasma membrane (Figure 10A). LPS treatment
did not cause an increase in enterocyte CD14 expression in
TLR-4/ mice. Additionally, LPS did not cause an increase
in intestinal permeability in CD14/ mice (C57BL/6
CD14/; the Jackson Laboratory) (Figure 10B). Together,
these data suggest that the LPS-induced increase inajp.amjpathol.org - The American Journal of Pathology
Figure 8 Effect of LPS on TLR-4 and CD14 localization in ﬁlter-grown Caco-2 monolayers as assessed by immunostaining. Original magniﬁcation, 600.
LPS Modulation of Intestinal TJ Barrierenterocyte CD14 expression and membrane localization is
dependent on TLR-4 expression and that CD14 expression
is necessary for the LPS-induced increase in mouse intes-
tinal permeability.Discussion
A defective intestinal epithelial TJ barrier plays an impor-
tant pathogenic role in intestinal inﬂammation by allowing
increased intestinal permeation and systemic circulation of
gut-derived bacterial antigens.1,2 Previous clinical studies
have demonstrated a correlation between an increase in
intestinal permeability and plasma LPS levels and an
increase in disease activity in IBD.20e23 Although the
cause-and-effect relationship between a defective intestinal
TJ barrier and intestinal penetration of LPS and systemic
endotoxemia is well established,11,13,16e20,22 the effects of
clinically relevant concentrations of LPS on the intestinal
barrier remain unknown. Because LPS levels are signiﬁ-
cantly elevated during physiological stresses and in intes-
tinal permeability disorders,20,22,24e28 and because
circulating LPS are an important determinant of inﬂamma-
tory response and multiorgan failure,11e13,16e19,22 under-
standing the effects of clinically relevant concentrations of
LPS on intestinal barrier function has important potentialThe American Journal of Pathology - ajp.amjpathol.orgclinical signiﬁcance. Herein, we show for the ﬁrst time that
physiologically and clinically relevant concentrations (0 to
10 ng/mL) of LPS cause an increase in intestinal epithelial
TJ permeability in vitro and in vivo, when present in the
interstitial ﬂuid or basolateral membrane compartment.
Consistent with the presence of high concentrations of
bacteria and LPS in the gut lumen, LPS in the apical
membrane surface did not affect the intestinal barrier
function. These data suggest that the high concentrations of
LPS present in the normal gut lumen do not affect intestinal
epithelial barrier function,14,15,25 but that relatively low
levels of LPS in the interstitial ﬂuid, which are readily
achievable during physiological stresses or in intestinal
permeability disorders, lead to an increase in intestinal
permeability.
In the healthy intestine, luminal LPS do not permeate
the intact intestinal epithelial barrier to any signiﬁcant
extent.14,15 However, in intestinal permeability disorders, the
defective TJ barrier allows paracellular permeation of LPS,
leading to elevated levels of LPS in the intestinal tissue and in
systemic circulation.11,16,17,20,22 LPS is a prototypical
pathogen-associated molecular pattern (PAMP) and binds to
a pattern recognition receptor (PRR).43,44 In the enterocytes,
TLRs play an integral role in the recognition of PAMPs.
Among the TLRs, TLR-4 is known to be the PRR for
LPS.43,45 Our data indicate that the TLR-4 levels are low in383
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Figure 9 Effect of LPS on CD14 expression in ﬁlter-grown Caco-2
monolayers. A: Time-course effect of LPS on CD14 expression. B: Effect of
siRNA CD14 transfection on Caco-2 TER. The mean TER for control Caco-2
monolayers was 482  15 U  cm2. C: Effect of siRNA CD14 transfection
on Caco-2 inulin ﬂux. D: Effect of siRNA TLR-4 transfection on expression of
CD14 in Caco-2 cells. Scr, scrambled. *P < 0.001 versus control; **P <
0.001 versus LPS treatment.
Guo et alquiescent Caco-2 cells and healthy mouse enterocytes. LPS
produced a time-dependent increase in TLR-4 expression in
Caco-2 cells, and by day 4 to 5, a marked increase in TLR-4
expression was observed. The time course of TLR-4
expression paralleled the increase in Caco-2 TJ perme-
ability; targeted knockdown of TLR-4 expression or phar-
macological inhibition of the TLR-4 signal transduction
pathway prevented the LPS-induced increase in Caco-2 TJ
permeability, demonstrating the requirement of TLR-4 and
the activation of the signal transduction pathway in mediating
the LPS-induced increase in Caco-2 TJ permeability. The
possibility of TLR-2 or TLR-5 involvement was also
considered, but LPS did not affect the expression of TLR-2 or
TLR-5, and siRNA-induced silencing of TLR-2 or TLR-5 did
not prevent the LPS-induced increase in intestinal TJ
permeability, conﬁrming that the LPS effect is regulated
speciﬁcally by the TLR-4 signal transduction pathway.
Consistent with our data, previous studies have also shown
low or undetectable levels of TLR-4 in healthy human
intestine and markedly elevated TLR-4 expression in patients
with IBD or NEC.43,45 An important potential implication of
these ﬁndings is that the increase in TLR-4 expression could
be an important pathogenic mechanism contributing to the
persistent increase in intestinal permeability and prolonga-
tion of intestinal inﬂammation in IBD and NEC.22384Sheth et al46 previously reported that a LPS concentration
of 500 ng/mL causes an acute drop in NRC-1 cholangiocyte
monolayer TER, with associated changes in junctional
localization of TJ proteins [occludin and Zona occludens
protein 1 (ZO-1)]. The LPS effect on NRC-1 TJ perme-
ability also required a rapid increase (within minutes) in
tyrosine phosphorylation of TJ proteins and myosin light
chain kinase activation, suggesting that the LPS-induced
increase in NRC-1 TJ permeability was mediated by an
acute signaling process leading to an activation of tyrosine
kinase and myosin light chain kinase.46 By contrast, in our
studies, the lower concentration of LPS (0 to 20 ng/mL) did
not cause an acute change in TJ permeability or TJ protein
localization in intestinal monolayers, but did cause
a delayed increase in intestinal TJ permeability (4 to 5 days),
which was dependent on TLR-4 expression. In our prelim-
inary studies, we also examined the possibility that NF-kB
activation may play a role in LPS modulation of Caco-2 TJ
permeability. These studies suggest that the LPS-induced
increase in TLR-4 expression leads to an activation of NF-
kB. Our initial studies also suggests that siRNA-induced
knockdown of NF-kB and/or p65 prevents the LPS-
induced increase in Caco-2 TJ permeability. These studies
suggest the possibility that NF-kB may be an important
down-stream mediator of LPS. An important focus of our
future studies will be to validate the role of NF-kB and to
delineate the molecular mechanisms by which LPS modu-
lates the intestinal TJ barrier.
Previous studies have indicated that the membrane-
associated protein CD14 forms a receptor complex with
TLR-4 and MD2, and plays an important role in the recog-
nition of LPS/LPS binding protein (LBP) complex and in
facilitating the interaction with TLR-4.43,44 LBP is a lipid
transfer protein that catalyzes the transfer of LPS monomer to
a binding site on CD14 via a ternary complex of LBP-LPS-
CD14, to form a monomeric LPS-CD14 complex. CD14
then transfers LPS to TLR-4/MD2.47e52 The LPS effect on
biological activity may be CD14 dependent or indepen-
dent.44,53 Our data suggest that CD14 also plays an integral
role in the modulation of intestinal TJ barrier. Immuno-
staining studies have shown that the LPS-induced increase in
plasma membrane TLR-4 expression and aggregation is
associated with an increase in CD14 membrane expression
and colocalization, consistent with the formation of the TLR-
4 receptor cluster.43,44 The requirement of CD14 membrane
localization in LPS modulation of the Caco-2 TJ barrier was
conﬁrmed by siRNA silencing studies, which showed that
CD14 knockdown inhibited the LPS-induced increase in
Caco-2 TJ permeability. These ﬁndings indicate that the
plasma membrane expression and colocalization of CD14
and TLR-4 are prerequisites for the LPS modulation of the
Caco-2 TJ barrier. Another novel ﬁnding related to the CD14/
TLR-4 interaction in the modulation of Caco-2 TJ barrier is
the dependence of enterocyte CD14 expression and
membrane localization on TLR-4 expression. Our results
show that CD14 expression and membrane localization areajp.amjpathol.org - The American Journal of Pathology
Figure 10 Effect of LPS (0.1 mg/kg body weight) on TLR-4 and
CD14 expression on mouse intestinal tissue in vivo. A: Effect of LPS
on TLR-4 and CD14 localization on mouse intestinal tissue as
assessed by immunostaining. Original magniﬁcation, 600. B: Effect
of LPS on intestinal permeability in CD14/ mice. *P < 0.001
versus wild-type (WT) control; **P < 0.001 versus WT LPS treatment.
LPS Modulation of Intestinal TJ Barrierdependent on TLR-4 expression; and that targeted knock-
down of TLR-4 prevents the LPS-induced increase in CD14
expression and membrane localization in Caco-2 cells and
mouse enterocytes. Thus, our data suggest for the ﬁrst time
that TLR-4 is an important regulator of CD14 expression in
enterocytes.
Previous studies have shown that in Caco-2 monolayers,
high pharmacological concentrations of LPS (50 mg/mL to 1
mg/mL) cause rapid intestinal epithelial cell death (within 1
to 2 hours of LPS treatment), leading to a loss of epithelial
integrity.30,31 Similarly, intraperitoneal injection of a high
lethal dose (10 mg/kg) of LPS in mice and rats also resulted
in rapid (within 2 to 3 hours) intestinal mucosal damage,The American Journal of Pathology - ajp.amjpathol.orgwith epithelial cell apoptosis and rapid loss of intestinal
barrier function.32 However, these high LPS concentrations
are not clinically achievable.33,34 At these high pharmaco-
logical concentrations, LPS-treated mice were very sick, and
most died shortly after the treatment.32,54,55 Our in vitro
studies indicate that LPS, at physiologically or clinically
relevant concentrations (0 to 10 ng/mL), does not cause cell
death, but leads to a selective increase in Caco-2 para-
cellular permeability. To assess the in vivo effects of
LPS, we also developed an in vivo mouse model of LPS
modulation of intestinal barrier function, which closely
recapitulates the plasma LPS levels reported in the clinical
studies.11e13,24e27 To establish the appropriate LPS dose to385
Guo et aluse in the in vivo studies, mice were injected i.p. with
increasing concentrations of LPS. These studies indicate
that a LPS dose of 0.1 mg/kg produces LPS plasma levels
(peak level of 2.23 ng/mL and trough level of 0.41 ng/mL)
that are achievable in clinical studies (Table 1). The LPS
dose of 10 mg/kg, which had been used in previous animal
studies,32 resulted in a very high plasma LPS level (peak
level of 13.49 mg/mL and trough level of 252.4 ng/mL) that
was not achievable clinically and led to rapid intestinal
mucosal damage and apoptosis. LPS at the dose used (0.1
mg/kg) in this study did not cause any apparent illness or
intestinal mucosal damage in the LPS-treated mice (data not
shown), and produced a similar time-course effect on mouse
intestinal permeability as the in vitro studies with Caco-2
monolayers. The increase in mouse intestinal permeability
was associated with an increase in TLR-4 expression in
mouse enterocytes; and the increase in intestinal perme-
ability was inhibited in TLR-4/ mice, indicating the
requirement of TLR-4 in the LPS-induced increase in mouse
intestinal permeability. Our in vivo studies also suggest that
the increase in mouse intestinal permeability is due to
a TLR-4edependent increase in enterocyte CD14 expres-
sion and membrane colocalization. Together, these in vivo
studies show that the LPS-induced increase in mouse
intestinal permeability is mediated by an increase in enter-
ocyte membrane expression of TLR-4, and TLR-4e
dependent expression and colocalization of CD14.
In conclusion, LPS at physiologically relevant concen-
trations cause an increase in intestinal TJ permeability
in vitro and in vivo, without inducing epithelial cell death or
intestinal mucosal damage. The LPS effect on intestinal TJ
permeability in vitro and in vivo is mediated by an increase
in enterocyte expression and membrane localization of
TLR-4, and TLR-4edependent expression and colocaliza-
tion of CD14. An important potential clinical implication of
these studies is that LPS, at physiologically relevant
concentrations, causes an increase in intestinal permeability
and could play an important role in further deterioration and
prolongation of intestinal TJ barrier defect in intestinal
permeability disorders and inﬂammatory diseases of the gut.
These data also show for the ﬁrst time that TLR-4 signal
transduction pathway plays an important role in intestinal
barrier regulation and may be targeted therapeutically.
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